{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:52Z","timestamp":1793710012443,"version":"4.6.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1706,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/jto.0b013e31820a443f","type":"journal-article","created":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T02:37:09Z","timestamp":1296614229000},"page":"786-789","source":"Crossref","is-referenced-by-count":15,"title":["Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Martin J.","family":"Edelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Malpass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak D.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31820a443f_bib1","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib4","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1073\/pnas.93.13.6610","article-title":"Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI","volume":"93","author":"Young","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/JTO.0b013e31820a443f_bib5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(01)01810-7","article-title":"Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species","volume":"51","author":"Magda","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31820a443f_bib6","article-title":"Motexafin gadolinium synergizes with anti-tumor agents docetaxel, pemetrexed and erlotinib in lung cancer cell lines and mouse xenograft tumors","volume":"47","author":"Naumovski","year":"2006","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"10.1097\/JTO.0b013e31820a443f_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0360-3016(99)00274-6","article-title":"In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer","volume":"45","author":"Miller","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31820a443f_bib8","doi-asserted-by":"crossref","DOI":"10.1090\/S0002-9939-01-05930-5","article-title":"Motexafin gadolinium (MGd): a redox active drug that enhances tumor response to chemotherapy","author":"Miller","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib9","first-page":"3215","article-title":"Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin","volume":"7","author":"Miller","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31820a443f_bib10","first-page":"229","article-title":"The redox mediator motexafin gadolinium (MGd) enhances the activity of several chemotherapy drugs","volume":"22","author":"Magda","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib12","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2002.07.500","article-title":"Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points","volume":"20","author":"Mehta","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2008.05.068","article-title":"Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial","volume":"73","author":"Mehta","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31820a443f_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e31820a443f_bib15","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0360-3016(00)01566-2","article-title":"Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity","volume":"49","author":"Xu","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31820a443f_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1148\/radiology.212.3.r99se10755","article-title":"Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases","volume":"212","author":"Viala","year":"1999","journal-title":"Radiology"},{"key":"10.1097\/JTO.0b013e31820a443f_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/jp9838588","article-title":"One-electron reduction and oxidation studies of the radiation sensitizer gadolinium (III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins","volume":"103","author":"Sessler","year":"1999","journal-title":"J Phys Chem"},{"key":"10.1097\/JTO.0b013e31820a443f_bib19","first-page":"739","article-title":"A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging","volume":"5","author":"Rosenthal","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31820a443f_bib20","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1200\/JCO.2001.19.7.2074","article-title":"Multicenter phase Ib\/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases","volume":"19","author":"Carde","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib21","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1097\/01.JTO.0000283402.21334.01","article-title":"Motexafin Gadolinium (MGd) is active as a single agent in advanced non-small-cell lung cancer (NSCLC) patients who failed platinum-based chemotherapy: preliminary results of a phase II trial: PD3\u20131-8","volume":"2","author":"Natale","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib22","article-title":"Combination motexafin gadolinium (MGd) and docetaxel is active in recurrent lung and other solid tumors: results of a phase 1 trial","volume":"24","author":"Pandya","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31820a443f_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/JTO.0b013e31811f4719","article-title":"Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer","volume":"8","author":"William","year":"2007","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415333955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415333955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T04:25:16Z","timestamp":1559967916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415333955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1556086415333955"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31820a443f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}